Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Obicetrapib on Contraceptive PK
NCT06250205Phase 1Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Feb 2024
- Primary completion
- Apr 2024
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of obicetrapib in dyslipidemia (2 arms), sponsored by NewAmsterdam Pharma. Primary endpoints: Maximum observed plasma concentration at Day 12 and Area under the plasma concentration-time curve at Day 12. Started Feb 2024; status: completed.
02
Drugs
obicetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT06250205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06250205.